POINT Biopharma Correlations
PNTDelisted Stock | USD 9.06 0.10 1.09% |
The current 90-days correlation between POINT Biopharma Global and Oric Pharmaceuticals is -0.09 (i.e., Good diversification). The correlation of POINT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
POINT Biopharma Correlation With Market
Good diversification
The correlation between POINT Biopharma Global and DJI is -0.03 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding POINT Biopharma Global and DJI in the same portfolio, assuming nothing else is changed.
POINT |
Moving together with POINT Stock
0.66 | PTAIF | PT Astra International | PairCorr |
0.72 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
0.61 | HD | Home Depot | PairCorr |
Moving against POINT Stock
0.41 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.35 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
0.34 | BKRKF | PT Bank Rakyat | PairCorr |
0.34 | PPERF | Bank Mandiri Persero | PairCorr |
0.34 | PG | Procter Gamble Sell-off Trend | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between POINT Stock performing well and POINT Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze POINT Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ORIC | 2.86 | (0.25) | 0.00 | (0.03) | 0.00 | 5.64 | 23.18 | |||
LYRA | 4.22 | (0.57) | 0.00 | (0.32) | 0.00 | 10.53 | 41.07 | |||
INBX | 2.25 | 0.02 | (0.01) | 0.13 | 2.71 | 5.54 | 16.80 | |||
EPIX | 4.60 | (0.95) | 0.00 | (0.39) | 0.00 | 9.30 | 84.61 | |||
CRNX | 1.69 | 0.02 | 0.00 | 0.12 | 2.41 | 3.67 | 16.75 | |||
ALXO | 3.61 | (0.71) | 0.00 | (0.26) | 0.00 | 9.30 | 22.71 | |||
IMTX | 1.99 | (0.51) | 0.00 | (0.71) | 0.00 | 3.84 | 22.12 | |||
BCAB | 4.45 | (0.17) | (0.02) | 0.00 | 4.76 | 12.86 | 31.41 | |||
AVTE | 2.39 | 0.42 | 0.16 | 0.54 | 2.09 | 5.58 | 19.11 | |||
CERE | 0.77 | 0.09 | (0.03) | (0.59) | 0.94 | 1.91 | 6.40 |
View POINT Biopharma Related Equities
Risk & Return | Correlation |
POINT Biopharma Corporate Management
MPH MPH | Ex Devel | Profile | |
FRCSC MD | Chief Director | Profile | |
Ari Shomair | VP Staff | Profile | |
Joe McCann | CEO Director | Profile | |
Donna BA | VP HR | Profile | |
RPh Herle | Ex Affairs | Profile | |
BBA FCA | Chief Officer | Profile |
Still Interested in POINT Biopharma Global?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.